Pluri

This week our Chief Technology Officer Lior Raviv will attend Advanced Therapies USA 2024. He will be the moderator for the “Staying agile and embracing technological innovations to optimize cell therapy manufacturing” panel and for the “Building your supply chain from scratch” panel. If you would like to set up a meeting with Lior feel free to DM us! #conference #healthcare #innovation #celltherapy #biotechnology

Pluri is pleased to announce that we have entered into a Memorandum of Understanding with Brainstorm Cell Therapeutics for the manufacturing of NurOwn®, a cell therapy candidate under investigation for amyotrophic lateral sclerosis (ALS). This collaboration marks an important step in supporting BrainStorm’s Phase 3b clinical trial and their continued efforts to advance potential treatments for ALS. Under this MOU, we will provide GMP-compliant manufacturing services at our manufacturing facility, facilitating the production of NurOwn® for use in the trial. We are committed to leveraging our experience and robust technology platform to help advance the development of novel therapies for a wide range of diseases, and we are optimistic about the potential impact of this collaboration. #Pluri #ALS #CellTherapy #NeurodegenerativeDiseases #GMPManufacturing #ClinicalTrials #Innovation #Healthcare Chaim Lebovits Nimrod Bar Zvi Yaky Yanay Andy Lewin Lior Raviv

Check out this article by Samantha Noon, featured on AgriFutures growAG, highlighting our innovative partnership with ICL Group: https://lnkd.in/d_66hwt9 This unique collaboration combines Pluri’s 3D cell expansion technology with ICL’s expertise in specialty minerals to drive biotechnological advancements in sustainable agriculture. Together, we are scaling cutting-edge bioactive carriers and biostimulant products in order to transform biostimulant delivery, and sustainably enhance yield. We’re thrilled to be pushing the boundaries of agricultural innovation and look forward to the success we will achieve together! 🌍☘ #Innovation #SustainableAgriculture #AgTech #Partnership #PlantNutrition #Biotechnology #ICL Tammy Sharon 🇮🇱 Ziv Kohav

Our CEO and President Yaky Yanay recently gave a presentation titled From Birth to Renewal: The Therapeutic Potential of Placental Cells to Promote Healthy Longevity at the Longevity Nation 2024 conference. Watch his full presentation by following the link below. #conference #biotechnology #celltherapy #foodtech #agtech #longevity #innovation #health #aging

This week, Pluri’s VP of Clinical Development, Michal sheleg, and Director of Cell Engineering Research, Adi Sharbi Yunger 🇮🇱, will be attending Society for Immunotherapy of Cancer (SITC) 2024. Following the recent launch of our immunotherapy platform, we are eager to learn more about the latest innovations and connect with experts in the field to explore new opportunities in advancing treatments for solid tumors. If you would like to set up a meeting please DM us! #SITC2024 #Immunotherapy #SolidTumors #CancerResearch #biotechnology

Our Chief Business Development Officer Efrat Kaduri will be attending Bio-Europe this week. DM us if you would like to set up a meeting with her! https://lnkd.in/dnuNZ2D #biotechnology #conference #lifescience #BIOEurope

In today’s volatile market, it's easy for innovative companies to be overlooked. A recent article featured in Investing.com highlights Pluri (NASDAQ: PLUR) as one of the most undervalued stocks on Wall Street, and we couldn't agree more! Our estimated asset value far exceeds our current valuation. We believe this discrepancy highlights an incredible opportunity for investors to recognize Pluri's true worth. Want to learn why? Click the link below: https://lnkd.in/d2j4gc98 #Pluri #Investing #Biotechnology #UndervaluedStocks #Innovation

Check out this insightful article in BioProcess International by our Chief Technology Officer, Lior Raviv, and Chief Commercial Officer of PluriCDMO, Andy Lewin. They delve into the critical role of CDMOs in overcoming scalability challenges to propel the advancement of cell therapies. Don’t miss their expert perspectives on this vital topic!💡 #biotechnology #innovation #cdmo #celltherapy Quantum Media Group, LLC Professor Ari Zoldan

We’re excited to announce our collaboration with BIRAD, supported by the Israel Innovation Authority, to advance the continued development of MAIT Cells for solid tumors, led by Prof. Cyrille Cohen Head of the laboratory of tumor immunology and immunotherapy at Bar-Ilan University. This partnership will integrate Prof. Cohen's innovative Siglec-based Chimeric Switch Receptors into Pluri’s CAR-MAIT cell therapy platform, enhancing its efficacy and tumor specificity. Together, we’re paving the way for breakthroughs in cancer care! 🌟 Read the full release by following the link: https://lnkd.in/dhQqG8D7 BIRAD – Research & Development Company Ltd. Israel Innovation Authority רשות החדשנות Merav Burstein Assaf Sagiv Anat Lev-Confortes #Pluri #CancerImmunotherapy #MAITCells #Innovation #Biotech

Check out this exclusive TechBullion interview with our CEO and President, Yaky Yanay, and Advisory Board member James Roosevelt, as they discuss Pluri's innovative cell therapies targeting age-related diseases and promoting longevity. In the interview, Yaky highlights our commitment to scalable, allogeneic cell therapies, while Jim emphasizes our focus on making healthcare accessible for all. Together, they showcase how Pluri aims to revolutionize eldercare and enhance global wellbeing. Read the full interview: https://lnkd.in/d6Tfh4eP And don’t miss Yaky’s presentation at the Longevity Nation conference next week, where he’ll share more about our vision! #Pluri #HealthcareInnovation #Aging #celltherapy Quantum Media Group, LLC Professor Ari Zoldan